Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (September 2015)
33 slides from Relmada Therapeutics's investor presentation, Sep 23, 2015
Slide 1: Relmada Therapeutics: Innovations in Pain Medicine
RELMADA THERAPEUTICS Innovations in Pain Medicine™ September 2015 Ticker Symbol OTCQB:RLMD
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or in other documents of Relmada Therapeutics (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward- looking statements.” These
Slide 3: Company Highlights
Company Highlights Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain Three products combine proven drug candidates with novel delivery methods to create new drugs with new indications, while the fourth i
Slide 4: Experienced Senior Management
Experienced Senior Management An impressive track record developing and commercializing successful drugs Sergio Traversa, PharmD Chief Executive Officer Douglas Beck, CPA Chief Financial Officer Michael Becker Senior VP, Finance & Corp Dev Richard Mangano, Ph.D. Senior VP, Clinical Dev Lisa Nolan, P
Slide 5: Scientific Advisors
ot RELMADA Scientific Advisors Internationally recognized expertise from world-class scientific advisors Memorial Sloan Kettering Imperial College & JOHNS HOPKINS Cancer Center. London Beate Andrew Rice, MD, FRCA Eric C. Strain, MD Paik Research at inperal Professor et sychaty,Jonns Hopkins Univrsty
Slide 6: Pain: Largest U.S. Public Health Crisis
RELMADA Pain: Largest U.S. Public Health Crisis Prevalence 100M: ., persistent Pain Annual Healthcare & Productivity Cost: $560-630 Billion’ 80M2 Disease ae Annual Healthcare & Productivity 328 Million Cost: $309 Billion’ Prescriptions and $13 Billion 29MP | cancer Annual Healthcare & Productivity i
Slide 7: Unsatisfied Market
Unsatisfied Market Better pain drugs are needed of chronic pain patients currently <= using opioids say they have “only a little” or “no control” over their pain. i) of patients report that opioids are “very | effective” in controlling chronic pain. Source: Voice of Chronic Pain A llational Study Co
Slide 8: Portfolio Covers Entire Chronic Pain Spectrum
ot RELMADA Portfolio Covers Entire Chronic Pain Spectrum Products in Market 2014 Sales ($M) Relmada Product Candidates Kadian@** Avinz KsvncapieR EL-1015 Severe Opana@* Nucynta¢ OxyContin® BuTab Vicodin®* REL-1028 Ultramé Moderate BuTran: Suboxone‘ a Lyricaé Cymbalta®** Gabapentin®* Mild ‘Lidode des
Slide 9: Robust Product Portfolio
ev RELMADA d-Methadone REL-1017 LevoCap ER REL-1015 MepiGel REL-1021 Robust Product Portfolio Significant value creation possible in 12-24 months due to accelerated development timelines resistant form of broad ‘spectrum opioid levorphanol Topical gel dosage form of local anesthetic mepivacaine Pre-
Slide 10: d-Methadone (REL-1017, dextromethadone)
d-Methadone (REL-1017, dextromethadone) Novel NMDA antagonist for the treatment of neuropathic pain ef RELMADA
Slide 11: d-Methadone: A New Drug for the Treatment of NP
RELMADA d-Methadone — A New Drug for the Treatment of NP Neuropathic pain represents a multi-billion market opportunity ready for a new effective entry + d-Methadone is a novel drug — Potential new treatment for >6 milion patients suffering from the most commonly studied chronic neuropathic pain sub
Slide 12: NMDA Receptor: Validated Target in Neuropathic Pain
RELMADA NMDA Receptor — Validated Target in Neuropathic Pain Safety of some antagonists, such as ketamine, precludes clinical use aun 2D * Glutamate is the neurotransmitter that binds as an agonist to the NMDA receptor propagating neurotransmission of pain signals + demethadone is a non-competitive
Slide 13: d-Methadone: Single Ascending Dose Study
SS ot RELMADA d-Methadone — Single Ascending Dose Study * Study was conducted in 42 healthy, opioid naive subjects * The objective was to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of oral single ascending doses of d-Methadone in healthy subjects in order to establish a
Slide 14: d-Methadone Next Steps
et RELMADA d-Methadone Next Steps Multiple development milestone potential in next 12-24 months H1 2015 H2 2015 2016* Y Complete Phase! single dose study in 42 subjects se! multi dose stu File IND and start Phase Il proof of concept study in PHN WV interim * Future milestones subject to capital
Slide 15: LevoCap ER (REL-1015)
LevoCap ER (REL-1015) Extended release, abuse resistant form of broad spectrum opioid levorphanol
Slide 16: LevoCap ER: Benefits, Advantages, Features
RELMADA LevoCap ER - Benefits, Advantages, Features LevoCap ER will compete in the $8.5 billion opioid market if approved + LevoCap ER is an extended release, abuse deterrent, patent protected formulation of levorphanol + Levorphanol is a unique, broad spectrum opioid with additional “non-opioid” me
Slide 17: How LevoCap ER Works
ot RELMADA How LevoCap ER Works Levorphanol’s multi-modal mechanism of action provides for a more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Non-Opioid Mechanism Ascending Pathways Descending Pathways Works to inhibit pain by Ser
Slide 18: Levorphanol's Broad Spectrum Activity
Pad RELMADA Levorphanol’s Broad Spectrum Activity Levorphanol’s multi-modal mechanism of action provides fora more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Non-Opioid Mechanism K Traditional Mu Opioid Receptors Serotonin Reupta
Slide 19: LevoCap ER Next Steps
RELMADA LevoCap ER Next Steps Multiple development milestone potential in next 12-24 months H1 2015 H2 2015 2016* 2017* + Start Phase il + Potential partnership * Future milestones subject to capital 19
Slide 20: BuTab (REL-1028)
BuTab (REL-1028) First oral tablet form of buprenorphine for treating both pain and addiction
Slide 21: BuTab: Benefits, Advantages, Features
BuTab — Benefits, Advantages, Features The first form of buprenorphine in a tablet for use in pain and treating addiction Buprenorphine is a partial opioid o5 agonist with two indications: addiction and pain No “traditional oral tablet” available for buprenorphine — Historically suffers from poor or
Slide 22: Buprenorphine Landscape
ot RELMADA Buprenorphine Landscape Nearly a $2 billion annual market for pain and opioid addiction indications Pain Therapy Opioid Addiction (>$500 Million Market Opportunity’) (-$1.8 Billion Market?) Sublingual Film/Tablet & Buccal Patch Sublingual Film/Tablet & Buccal Patch Product Status Product
Slide 23: Potential Outcomes
RELMADA Potential Outcomes From current Phase 1 study with various BuTab formulations jal out ent PI i Additional
Slide 24: BuTab Next Steps
RELMADA BuTab Next Steps Multiple development milestone potential in next 12-24 months H12015 'H22015' 2016" ' 2017* * Future milestones subject to capital
Slide 25: MepiGel (REL-1021)
MepiGel (REL-1021) Topical gel dosage form of the local anesthetic mepivacaine for the treatment of neuropathic pain RELMADA
Slide 26: MepiGel: Benefits, Advantages, Features
eo? RELMAD MepiGel — Benefits, Advantages, Features MepiGel will compete with Lidoderm® patch and its $948 million in peak sales if approved « MepiGelis the first topical gel dosage form of local anesthetic mepivacaine, which has intrinsic vasoconstrictor attributes — Reduces rate at which drug is c
Slide 27: MepiGel Next Steps
SS rad RELMADA MepiGel Next Steps Multiple development milestone potential in next 12-24 months H1 2015 H2 2015 2016* 2017* Complete formulation work Select formulation File al Trial Application (CTA) Ci Phasel in ~20 patients * Future milestones subject to capital 7
Slide 28: Milestones & Commercial Opportunity
MILESTONES & COMMERCIAL OPPORTUNITY et RELMADA
Slide 29: Near-term Value Drivers
RELMADA Near-term Value Drivers Multiple development milestone potential in next 12-24 ¥ Completed Phase | d-Methadone [iauberseaiinees REL-1017 42 subjects ¥ Obtain regulatory LevoCap ER approval from Health REL-1015 Canada to start clinical trial ¥ Obtain regulatory ‘approval from Health Canada to
Slide 30: Recent Deal Flow and Financing
i et RELMADA Recent Deal Flow and Financing Activity fits well with Relmada’s pipeline NMD. antagonists Opioids Jun 2015 ~ Spinitex Jul 2015—Naurex Jan 2015~Depomed ‘acquired by Novartis for ‘acquired by Allergan for ‘equires US. ightsto ~$700 milion, +5860 million, Phase 3 Nucynta® from Johnson ang
Slide 31: Financial Snapshot
eo ee ot RELMADA Financial Snapshot Ticker RLMD (oTcaB) Cash & Equivalents m, ii; (as of 6/30/15) $22.4 million Operating Expenses =n (three months ended 3/31/15) eo pallet Common Shares Outstanding 7 al (as of 9/11/15) 10.8 million 52-Week Stock Price Range $4.11 to $20.00
Slide 32: Company Highlights
RELMADA Company Highlights e Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain @ Three products combine proven drug candidates with novel delivery methods to create new drugs with new indications, while
Slide 33: Relmada Therapeutics contact
ef RELMADA THERAPEUTICS Innovations in Pain Medicine™ 757 Third Avenue, 20th FI. New York, NY 10017 www.relmada.com Email: info@relmada.com Ticker Symbol OTCQB:RLMD
Relmada Therapeutics — Investor Presentation (September 2015) on 6ix